Improvement of quality of life in women using a low-dose desogestrel-containing contraceptive: Results of an observational clinical evaluation

European Journal of Contraception and Reproductive Health Care

Volumn 7, Issue 4, 2002, Pages 238-243

  Ernst, U ^a,c   Baumgartner, L ^b   Bauer, U ^b   Janssen, G ^b  

^a Organon Germany   (Germany)

^b Private Eye Clinic   (Germany)

^c Clinical Research   (Germany)

Author keywords

Desogestrel; Oral contraception; Quality of life

Indexed keywords

DESOGESTREL; ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BLEEDING; CONTROLLED STUDY; EVALUATION; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MOOD; ORAL CONTRACEPTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SEXUAL BEHAVIOR;

EID: 0037002631     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.1080/ejc.7.4.238.243     Document Type: Article

References (23)

1. Gerstman BB, Piper JM, Tornita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991;133:32-7
2. Lidegaard O, Edstroem B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002;65:187-96
3. Vessey MP. Female hormones and vascular disease - an epidemiological overview. Br J Fam Plann 1980;6:1-12
4. Helmerhorst FM, Bloemenkamp KWM, Rosendaal FR, Vandenbroucke JP. Oral contraceptives and thrombotic disease: risk of venous thromboembolism. Thromb Haemost 1997;78:327-33
5. Guillebaud J. Contraception - Your Questions Answered, 3rd edn. Edinburgh: Churchill Livingstone, 1999
6. Fotherby K. Clinical experience, and pharmacological effects of an oral contraceptive containing 20 μg oestrogen. Contraception 1992;46:477-88
7. Lammers P, op ten Berg M. Phase III clinical trial with new oral contraceptive containing 150 mcg desogestrel and 20 mcg ethinylestradiol. Acta Obstet Gynecol Scand 1991;70:497-500
8. Rossmanith WG, Wirth U, Gasser S, et al. Comparative study of ovarian activity, cycle stability and tolerance during administration of two low-dosage oral contraceptives. Zentralbl Gynakol 1997;119:538-44
9. Serfaty, D, Vree ML. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 μg ethinylestradiol and either 150 μg desogestrel or 75 μg gestodene. Eur J Contracept Reprod Health Care 1998:3:179-89
10. Castelo-Branco C, Martinez de Osaba MJ, Pons F, et al. Effects on bone mass of two oral contraceptives containing ethinylestradiol and cyproterone acetate or desogestrel: results of a 2-year follow-up. Eur J Contracept Reprod Health Care 1998;3:79-84
11. Egarter C, Topcuoglu MA, Imhof M, et al. Low dose oral contraceptives and quality of life. Contraception 1999;59:287-91
12. Endicott J, Nee J, Harrision W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993:29:321-6
13. Charoenvisal C, Thaipisuttikul Y, Pinjaroen S, et al. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate. Int J Fertil Menopausal Stud 1996;41:423-9
14. Mango D, Ricci S, Manna P, et al. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgans. Contraception 1996;53:163-70
15. Newton JR. Classification and comparison of oral contraceptives containing new generation progestogens. Hum Reprod Update 1995;1:231-63
16. Benagiano G, Primiero FM. Multicenter clinical trial of an oral contraceptive with desogestrel plus 20 mcg ethinylestradiol in Italy. In Newton, JR, ed. Mercilon; a New Era in Low-dose Oral Contraception; the Proceedings of a Symposium Held at the 13th World Congress on Fertility and Sterility, Marrakesh, October 1989. Carnforth, UK: Parthenon Publishing, 1990:55-63
17. Op ten Berg M. International multicenter clinical trial of an oral contraceptive containing 20 mcg ethinylestradiol and 150 mcg desogestrel (Mercilon). In Newton JR, op ten Berg M, eds. Optimizing the Estrogen Dose in Oral Contraceptives. Carnforth, UK: Parthenon Publishing, 1992:33-8
18. Kahn-Nathan J, Lapousterle C. Results of a national multicentre study of an oral contraceptive containing 20 mcg ethinylestradiol and 150 mcg desogestrel. Reprod Hum Horm 1991;4 (Suppl 1): 15-20
19. Deijen JB, Duyn KJ, Jansen WA, et al. Use of a low-dose oral contraceptive in relation to mental functioning. Contraception 1992;46:359-67
20. Åkerlund M, Roede A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of 2 oral contraceptive formulations containing 150 mcg desogestrel and either 30 mcg or 20 mcg ethinylestradiol. Br J Obstet Gynaecol 1993;100:832-8
21. Endrikat J, Jaques MA, Mayerhofer M, Pelissier C, Mueller U, Duesterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 mcg ethinylestradiol/75 mcg gestodene and 20 mcg ethinylestradiol/150 mcg desogestrel, with respect to efficacy, cycle control and tolerance, Contraception 1995:52:229-35
22. Tuiten A, Panhuysen G, Koppeschaar E, et al, Stress, serotonergic function, and mood in users of oral contraceptives. Psychoneuroendocrinology 1995;20:323-34
23. Endrikat J, Düsterberg B, Ruebig A, et al. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception 1999;60:269-74